San Francisco, July 19, 2018 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Chief Scientific Officer, Darrell Nix, Ph.D., will present the findings of a Phase 1 study of its lead drug candidate dutogliptin for the treatment of patients in early recovery post-myocardial infarction. The presentation will take place on August 25, 2018 in the Innovative Drug Therapies session scheduled at 2pm.
Entitled “Evaluation of the pharmacokinetics and pharmacodynamics of subcutaneously administered dutogliptin for daily injection with granulocyte colony stimulating factor (G-CSF) for AMI”, the presentation will summarize safety, tolerability, PK, and PD outcomes of dutogliptin to establish the dose for the Company’s Global Phase 2 study in Acute Myocardial Infarction. As reported previously, this Phase 2 study recently began recruiting patients in Europe.
Recardio’s regenerative therapeutic approach to minimize and repair the heart muscle injury that follows an infarction consists of mobilizing, recruiting, and homing stem cells in-vivo by using cytokines and inhibitors. Specifically, engraftment and an improvement in cardiac output are possible by mobilizing bone marrow stem cells into circulating blood with G-CSF and then initiating stem cell migration and homing to cardiac sites of ischemia or injury with dutogliptin, a small molecule inhibitor of dipeptidylpeptidase-IV (DPP-IV), the key enzyme responsible for degradation of stromal derived factor-1α (SDF-1), which is the major chemokine responsible for mobilization and migration of stem cells to areas of ischemic injury. The Phase 1 study to be presented by Dr. Nix was carried out to determine the safety and dosing required for the sustained availability of dutogliptin to inhibit DPP4 and sustain SDF-1.
“The safety, pharmacokinetics, and pharmacodynamics study to be presented at the ESC conference in Munich provided the foundation for the clinical evaluation of dutogliptin with G-CSF in AMI patients” said Roman Schenk, Executive Chairman of Recardio. “We look forward to sharing these significant outcomes.”
Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. The company is pursuing a Phase 2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/